- In patients with prostate cancer, intensity-modulated radiation therapy (IMRT) after prostatectomy was associated with favorable long-term QoL and late toxicity.
Why this matters
- Findings may help guide clinical decision-making in consideration of preserving QoL and limiting late toxicity.
- Prospective cohort study of 199 consecutive patients with prostate cancer who received IMRT after prostatectomy.
- Funding: None.
- Median follow-up, 33 months.
- QoL remained stable over time in all 5 domains with no decline at any point exceeding the minimally clinically important difference.
- 8%-18% of patients experienced a small effect; 0%-8% had moderate effect in multidomain decline up to 84 months.
- At 4 years, the rates of freedom from grade ≥2 genitourinary and gastrointestinal toxicity were 94% and 95%, respectively.
- Functional erections were recovered in 59% of patients recovered at month 36.
- At 4 years, no significant difference was seen in urinary continence and urinary function domains in patients who used 0, 1, or ≥2 pads/day at baseline.
- Use of sexual aid was stable at 7 years vs baseline.
- Factors associated with worse QoL: longer time to IMRT, higher BMI, older age, hormone therapy, dose, current tobacco use, and bladder volume receiving 70 Gy.
- Patients lost to follow-up.